

Loperamide Hydrochloride

Type of Posting
Posting Date
Official Date
Expert Committee

Revision Bulletin 29–May–2020 01–Nov–2020 Chemical Medicines Monographs 3


In accordance with the Rules and Procedures of the 2015–2020 Council of Experts, the Chemical Medicines Monographs 3 Expert Committee has revised the Loperamide Hydrochloride monograph. The purpose for the revision is to address the inadvertent omission of text that was published in the *Pharmacopeial Forum* (*PF*) and approved by the Expert Committee. Specifically, a revision for *Organic Impurities* was proposed in *PF* 43(4), and ultimately was approved by the Expert Committee; however, total impurities was inadvertently omitted from *Table 2* when the monograph was published as final approved text in the *USP-NF*.

In addition, the cross-reference to *Chromatography* <621> has been corrected from "Chromatography <621>, General Procedures, Thin-Layer Chromatography" to "Chromatography <621>, System Suitability" under *Chromatographic system* in the test for *Organic Impurities*.

The Loperamide Hydrochloride Revision Bulletin supersedes the currently official Loperamide Hydrochloride monograph.

Should you have any questions, please contact Andrea F. Carney, Scientific Liaison to the Chemical Medicines Monographs 3 Expert Committee (301-816-8155 or <u>afc@usp.org</u>).

Loperamide Hydrochloride



Click image to enlarge

 $C_{29}H_{33}CIN_2O_2 \cdot HCl$ 513.50

1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl- α , α -diphenyl-, monohydrochloride; 4-[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide hydrochloride [34552-83-5].

DEFINITION

Loperamide Hydrochloride contains NLT 98.0% and NMT 102.0% of loperamide hydrochloride ($C_{29}H_{33}CIN_2O_2 \cdot HCI$),

calculated on the dried basis.

IDENTIFICATION

- A.<u>Spectroscopic Identification Tests (197), Infrared Spectroscopy</u>: 197A or 197K
- B. IDENTIFICATION TESTS—GENERAL (191), Chemical Identification Tests, Chloride

Sample solution: Dissolve about 30 mg of Loperamide Hydrochloride in 0.5 mL of <u>methanol</u>. Add 1.5 mL of water and 1 mL of <u>6 N ammonium hydroxide</u>. A precipitate forms. Centrifuge, decant, and acidify the supernatant with diluted nitric acid.

Acceptance criteria: Meets the requirements

ASSAY

Change to read:

• PROCEDURE

Sample solution: Dissolve 400 mg of Loperamide Hydrochloride in 50 mL of alcohol and add 5.0 mL of 0.01 N hydrochloric acid.

Analysis: Titrate the Sample solution with 0.1 N sodium hydroxide VS (see <u>Titrimetry (541)</u>), determining the endpoint potentiometrically. Read the volume of 0.1 N sodium hydroxide added between the two points of inflection. Each milliliter of 0.1 N sodium hydroxide is equivalent to 51.35 mg of loperamide hydrochloride (C₂₉H₃₃ClN₂O₂·HCl). (USP

1-May-2020)

Acceptance criteria: 98.0%-102.0% on the dried basis

IMPURITIES

• **Residue on Ignition** (281): NMT 0.1%

Change to read:

• ORGANIC IMPURITIES

Solution A: 17.0 g/L of tetrabutylammonium hydrogen sulfate in water

Solution B: Acetonitrile

Mobile phase: See <u>Table 1</u>. Return to original conditions and re-equilibrate the system.

Table 1

Time	Solution A	Solution B
(min)	(%)	(%)
0	90	10

Time (min)	Solution A (%)	Solution B (%)
15	30	70
17	30	70

System suitability solution: 10 mg/mL of <u>USP Loperamide System Suitability Mixture RS</u> in <u>methanol</u>. See <u>Table 2</u> for the relative retention times of the main components of the mixture.

Standard solution: 20 µg/mL of USP Loperamide Hydrochloride RS in methanol

Sensitivity solution: 5 µg/mL of USP Loperamide Hydrochloride RS in methanol, from the Standard solution Sample solution: 10 mg/mL of Loperamide Hydrochloride in methanol

Chromatographic system

(See <u>Chromatography (621), ▲System Suitability</u> (RB 1-Nov-2020) •)

Mode: LC

Detector: UV 220 nm

Column: 4.6-mm × 10-cm; 3-µm packing L1

Column temperature: 35°

Flow rate: 1.5 mL/min

Injection volume: 10 µL

System suitability

Samples: System suitability solution, Standard solution, and Sensitivity solution

Suitability requirements

Peak-to-valley ratio: NLT 1.5 for loperamide *cis-N*-oxide and anhydroloperamide; NLT 1.5 for loperamide piperidinolamide and loperamide biphenyl analog, *System suitability solution*

Relative standard deviation: NMT 10.0%, Standard solution

Signal-to-noise ratio: NLT 10, Sensitivity solution

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of each individual impurity in the portion of Loperamide Hydrochloride taken:

Result =
$$(r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

 r_{U} = peak response of each impurity from the Sample solution

r_s = peak response of loperamide from the Standard solution

 C_{s} = concentration of <u>USP Loperamide Hydrochloride RS</u> in the *Standard solution* (mg/mL)

 C_{II} = concentration of Loperamide Hydrochloride in the Sample solution (mg/mL)

F = relative response factor (see <u>Table 2</u>)

Acceptance criteria: See <u>Table 2</u>.

Table 2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Chlorophenylpiperidinol	0.2	1.0	0.2
Deschloroloperamide	0.8	0.59	0.2
Loperamide	1.0	—	_
Loperamide <i>trans-N</i> -oxide	1.1	1.0	0.2
Loperamide <i>cis-N</i> -oxide	1.16	1.0	0.2
Anhydroloperamide	1.18	1.0	0.2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Loperamide	1.2	1.0	0.2
piperidinolamide	1.3	1.0	0.2
Loperamide biphenyl analog	1.4	0.77	0.2
Loperamide quaternary salt	1.7	1.0	0.2
Any other individual impurity	_	1.0	0.10▲ (USP 1-May-2020)
▲Total impurities	_	_	0.3 _{▲ (RB 1-Nov-2020)}

SPECIFIC TESTS

• Loss on Drying (731) Analysis: Dry at 105° for 4 h. Acceptance criteria: NMT 0.5% ADDITIONAL REQUIREMENTS • PACKAGING AND STORAGE: Preserve in well-closed containers. Change to read: • USP Reference Standards (11) USP Loperamide Hydrochloride RS USP Loperamide System Suitability Mixture RS The mixture contains loperamide hydrochloride and the following impurities (other impurities may also be present): Chlorophenylpiperidinol; 4-(4-Chlorophenyl)piperidin-4-ol. C₁₁H₁₄CINO 211.69 Deschloroloperamide; 4-(4-Hydroxy-4-phenylpiperidin-1-yl)-*N*,*N*-dimethyl-2,2-diphenylbutanamide. C29H34N2O2 442.59 Loperamide trans-N-oxide; (1r,4s)-4-(4-Chlorophenyl)-1-[4-(dimethylamino)-4-oxo-3,3-diphenylbutyl]-4-hydroxypiperidine 1-C20H33CIN2O3 493.04 oxide. Loperamide cis-N-oxide; (1s,4r)-4-(4-Chlorophenyl)-1-[4-(dimethylamino)-4-oxo-3,3-diphenylbutyl]-4-hydroxypiperidine 1-C29H33CIN203 493.04 oxide. Anhydroloperamide; 4-[4-(4-Chlorophenyl)-5,6-dihydropyridin-1(2H)-yl]-N,N-dimethyl-2,2-C29H31CIN20 diphenylbutanamide. 459.02 Loperamide piperidinolamide; 1,4-Bis[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-2,2-diphenylbutan-1-one. C₃₈H₄₀Cl₂N₂O₃ Loperamide biphenyl analog; 4-[4-(4'-Chlorobiphenyl-4-yl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2diphenylbutanamide. 553.13 C35H37CIN202

Loperamide quaternary salt; 4-(4-Chlorophenyl)-1,1-bis[4-(dimethylamino)-4-oxo-3,3-diphenylbutyl]-4-hydroxypiperidin-1-ium 778.85 (USP 1-May-2020) C₄₇H₅₃Cl₂N₃O₃ chloride.

Page Information:

Not Applicable

DocID:

© 2020 The United States Pharmacopeial Convention All Rights Reserved.

643.64